Reducing end-of-life costs will do little to curb the growth in Medicare spending overall. But end-of-life care provision should be reformed to match the values of patients.

The U.S. is not immune to lethal failings in the quality of pharmaceutical drugs. With little realistic oversight, and more importantly, little ethos of business integrity in China, a major tragedy in the U.S. from a Chinese export is likely in the near future.

The only way to improve the availability of these products is to make it possible for firms to keep pace with rising production costs and earn enough returns to invest back in better manufacturing that enables stable, safe, and more scalable supply.

Two recent experimental drugs demonstrate that new scientific principles are faster becoming superior medicines, but bad government policies threaten to reverse this trend.

Under President Obama’s health care plan, the United States Preventive Services Task Force now wields great power to decide which health services (like mammograms) doctors should provide, yet it has few checks on its sweeping authority.

While the FDA is trying to save patients from the harmful effects of new medicines,manymore patients will die waiting for the good medicines than from using bad ones.

Medical datais sealed up at the FDA, in applications and reports that researchers must file before receiving the agency's approval to conduct trials or market new drugs.